PMID- 1333351
OWN - NLM
STAT- MEDLINE
DCOM- 19930107
LR  - 20190827
IS  - 0171-967X (Print)
IS  - 0171-967X (Linking)
VI  - 51
IP  - 6
DP  - 1992 Dec
TI  - Factors predicting the acute effect of pamidronate on serum calcium in 
      hypercalcemia of malignancy.
PG  - 419-23
AB  - In this study we retrospectively reviewed results of the first 9 days of 
      treatment with pamidronate at doses of 30 mg (n = 13), 45 mg (n = 9), and 90 mg 
      (n = 13) in an attempt to see what factors influenced the response of serum 
      calcium to pamidronate. The nadir of serum calcium obtained post treatment was 
      correlated with pretreatment levels of nephrogenous cyclic adenosine 
      monophosphate (NcAMP), the renal tubular threshold for phosphate reabsorption 
      (TmPO4), and the renal tubular threshold for calcium reabsorption (TmCa). Using 
      the post treatment serum calcium levels, patients were divided into "good" and 
      "poor" responders depending on whether a normal serum calcium was obtained. 
      Pretreatment NcAMP was significantly correlated with the magnitude of the 
      response of serum calcium (r = 0.45, P = 0.0001). Pretreatment NcAMP was 
      significantly higher in the poor responders (mean +/- SEM): 65.0 +/- 9.4 
      nmol/liter GF (poor responders) versus 29.6 +/- 6.3 (good responders), P = 0.004. 
      NcAMP as a predictor of the acute response of serum calcium showed a sensitivity 
      of 93% and a specificity of 72%. Pretreatment TmPO4 was negatively correlated 
      with the serum calcium response post treatment (r = -0.41, P = 0.003). However, 
      though TmPO4 tended to be lower in the poor responders, this was not 
      statistically significant [0.65 mmol/liter GF +/- 0.09 (poor responders) versus 
      0.76 mmol/liter GF +/- 0.06 (good responders)]. As a predictor of the acute 
      response of serum calcium, TmPO4 was less good with a sensitivity of 70% and 
      specificity of 58%. No significant correlation was present between TmCa and the 
      serum calcium response.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Gallacher, S J
AU  - Gallacher SJ
AD  - University Department of Medicine, Glasgow Royal Infirmary, U.K.
FAU - Fraser, W D
AU  - Fraser WD
FAU - Logue, F C
AU  - Logue FC
FAU - Dryburgh, F J
AU  - Dryburgh FJ
FAU - Cowan, R A
AU  - Cowan RA
FAU - Boyle, I T
AU  - Boyle IT
FAU - Ralston, S H
AU  - Ralston SH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Calcif Tissue Int
JT  - Calcified tissue international
JID - 7905481
RN  - 0 (Diphosphonates)
RN  - 0 (Parathyroid Hormone)
RN  - 0 (Phosphates)
RN  - E0399OZS9N (Cyclic AMP)
RN  - OYY3447OMC (Pamidronate)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Absorption
MH  - Calcium/*blood
MH  - Cyclic AMP/*metabolism
MH  - Diphosphonates/administration & dosage/*therapeutic use
MH  - Humans
MH  - Hypercalcemia/blood/*drug therapy/etiology
MH  - Infusions, Intravenous
MH  - Kidney/metabolism
MH  - Neoplasms/*complications
MH  - Pamidronate
MH  - Parathyroid Hormone/blood
MH  - Phosphates/metabolism
MH  - Retrospective Studies
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
AID - 10.1007/BF00296674 [doi]
PST - ppublish
SO  - Calcif Tissue Int. 1992 Dec;51(6):419-23. doi: 10.1007/BF00296674.